Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 8/20 | 0.46 |
| ▸ | NOS2 | P35228 | 8/20 | 0.46 |
| ▸ | NOS1 | P29475 | 5/20 | 0.46 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | CCR8 | P51685 | 1/20 | 0.41 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | USP7 | Q93009 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30684515 | 1.00 | NOS3 (0.46) | NOS3NOS2NOS1CCR1CCR5 | |
| SCHEMBL2482691 | 0.81 | NOS3 (0.48) | NOS3NOS2NOS1CCR1CCR5 | |
| SCHEMBL5809638 | 0.79 | NOS3 (0.46) | NOS3NOS2NOS1CCR1CCR5 | |
| SCHEMBL13485983 | 0.79 | NOS3 (0.41) | NOS3NOS2NOS1UHRF1MAP4K4 | |
| SCHEMBL3840770 | 0.79 | NOS3 (0.42) | NOS3NOS2NOS1CCR1CCR5 | |
| SCHEMBL29756246 | 0.79 | NOS3 (0.41) | NOS3NOS2NOS1UHRF1MAP4K4 | |
| Ammonia Solution, Strong SCHEMBL29016866 | 0.77 | NOS3 (0.44) | NOS3NOS2NOS1CCR1CCR5 | |
| SCHEMBL24753651 | 0.75 | NOS3 (0.39) | NOS3NOS2NOS1CCR1CCR5 | |
| SCHEMBL31568933 | 0.75 | NOS3 (0.38) | NOS3NOS2NOS1USP7 | |
| SCHEMBL21206805 | 0.75 | LMNA (0.44) | NOS3NOS2NOS1CCR1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117957219-A | Pyridine derivative and application thereof | 四川汇宇制药股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117279908-A | Heteroaryl compounds for the treatment of cognitive disorders | 加的夫大学学院咨询有限公司 | 2023-12-22 | — | — | CN | disclosed |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| US-20230146944-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | SIGNAL PHARMACEUTICALS, LLC | 2023-05-11 | — | — | US | disclosed |
| US-11529350-B2 | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| EP-3994132-A1 | TYROSINE KINASE NON-RECEPTOR 1 (TNK1) INHIBITORS AND USES THEREOF | Sumitomo Dainippon Pharma Oncology, Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| EP-3959207-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | Celgene Corporation (US) | 2022-03-02 | — | — | EP | disclosed |
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2021-03-18 | — | — | US | disclosed |
| WO-2021003417-A1 | TYROSINE KINASE NON-RECEPTOR 1 (TNK1) INHIBITORS AND USES THEREOF | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| US-20210000825-A1 | Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitors and Uses Thereof | SUMITOMO PHARMA ONCOLOGY, INC. | 2021-01-07 | — | — | US | disclosed |
| US-9278983-B2 | Fused heterocyclic compound and use thereof for pest control | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-03-08 | — | — | US | disclosed |
| US-20140364444-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF FOR PEST CONTROL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-12-11 | — | — | US | disclosed |
| US-8853238-B2 | Fused heterocyclic compound and use thereof for pest control | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-10-07 | — | — | US | disclosed |
| CN-103800313-A | Novel derivatives of cyclic compound and the use thereof | WONKISOPHARM CO LTD | 2014-05-21 | — | — | CN | disclosed |
| US-20140018373-A1 | FUSED HETEROCYCLIC COMPOUND AND USE FOR PEST CONTROL THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-01-16 | — | — | US | disclosed |
| CN-101547886-B | pharmaceutical composition and cosmetic composition | WONKISOPHARM CO LTD | 2013-08-21 | — | — | CN | disclosed |
| US-7655366-B2 | methoxy substitued dithienylethene as photochromic dyes; dispersed in solvent or polymer; reversible transition between colorless and colored state in response to light; erasable by heat or light, stability; ink jet printers; toner-free; cost efficiency; disposable paper reused; environmentally friendly | XEROX CORPORATION (US) | 2010-02-02 | — | — | US | disclosed |
| CN-101547886-A | Novel derivative of cyclic compound and use thereof | WONKISOPHARM CO LTD (KR) | 2009-09-30 | — | — | CN | disclosed |
| US-20080311489-A1 | INKLESS REIMAGEABLE PRINTING PAPER AND METHOD | XEROX CORPORATION (US) | 2008-12-18 | — | — | US | disclosed |
| WO-1997000256-A1 | POLYMORPHIC FORMS OF AN ANGIOTENSIN II ANTAGONIST | MERCK & CO., INC. (US) | 1997-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018373-A1 | FUSED HETEROCYCLIC COMPOUND AND USE FOR PEST CONTROL THEREOF | NR4A1, NR2C2, NR0B1 | NOS3 834/4885NOS2 1234/4885NOS1 859/4885 |
| US-20210000825-A1 | Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitors and Uses Thereof | TNK1, TNNI3K, TYK2 | NOS3 813/4885NOS2 1014/4885NOS1 590/4885 |
| US-11529350-B2 | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof | TNK1, TNNI3K, TYK2 | NOS3 813/4885NOS2 1014/4885NOS1 590/4885 |
| US-20140364444-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF FOR PEST CONTROL | NR4A1, NR2C2, NR0B1 | NOS3 755/4885NOS2 1161/4885NOS1 800/4885 |
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | CRHR2, CRHR1, CRH | NOS3 1614/4885NOS2 1129/4885NOS1 2176/4885 |
| US-20230146944-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CYP8B1, HAX1, HRH4 | NOS3 1702/4885NOS2 1393/4885NOS1 1392/4885 |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | CRHR2, CRHR1, CRH | NOS3 1614/4885NOS2 1129/4885NOS1 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.